[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-344725-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-344725-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","myc-at-the-tumorimmune-interface-mechanisms-of-immune-escape-and-immunotherapy-resistance","MYC at the tumor–immune interface - mechanisms of immune escape and immunotherapy resistance","","Immunotherapies have transformed cancer care by enabling immune recognition and elimination of malignant cells, yet many patients either fail to respond or later develop resistance. This review focuses on the oncogene MYC, deregulated in roughly 70% of human cancers, as a central driver of immune evasion and immunotherapy failure. It explains how MYC suppresses antigen processing and presentation, attenuates interferon signaling, and increases immune checkpoint expression. It also describes MYC-driven recruitment of immunosuppressive cell populations and metabolic remodeling that impairs effector T and NK cell function, supporting primary, adaptive, and acquired resistance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/myc-at-the-tumorimmune-interface-mechanisms-of-immune-escape-and-immunotherapy-resistance/344725/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/myc-at-the-tumorimmune-interface-mechanisms-of-immune-escape-and-immunotherapy-resistance/344725.png","ImageObject",300,407,{"name":42,"@type":43},"Patrick","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why do some patients fail to respond to cancer immunotherapy?","Question",{"text":63,"@type":64},"Many patients fail to respond to immune checkpoint inhibitors and other immunotherapies or later develop resistance. The review links this to immune evasion mechanisms driven by the oncogene MYC.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does MYC promote immune escape?",{"text":68,"@type":64},"MYC can suppress antigen processing and presentation, attenuate interferon signaling, and increase immune checkpoint molecules such as PD-L1 and CD47.",{"name":70,"@type":61,"acceptedAnswer":71},"What strategies does the review suggest for overcoming immunotherapy resistance?",{"text":72,"@type":64},"Targeting MYC directly or indirectly is proposed to restore immune surveillance and improve immunotherapeutic efficacy, helping to overcome multiple resistance pathways.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},344725,1790380875,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","TYPE Review  \nPUBLISHED 23 January 2026  \nDOI 10.3389/fimmu.2026.1738440  \nOPEN ACCESS  \nEDITED BY  \nChristian Klein,  \nLudwig Maximilian University of Munich, Germany  \nREVIEWED BY  \nJohn Knight,  \nThe University of Manchester, United Kingdom Javier Leon,  \nUniversity of Cantabria, Spain  \n*CORRESPONDENCE  \nSlvia Casacuberta-Serra  \n [scasacuberta@peptomyc.com](scasacuberta@peptomyc.com)[ ](scasacuberta@peptomyc.com)Laura Soucek  \n [lsoucek@vhio.net](lsoucek@vhio.net)  \nRECEIVED 03 November 2025  \nREVISED 16 December 2025  \nACCEPTED 05 January 2026  \nPUBLISHED 23 January 2026  \nCITATION  \nGonz´alez-Larreategui I´, Valde´s-Bango Martn M, Casacuberta-Serra S and Soucek L (2026) MYC at the tumor–immune interface: mechanisms of immune escape and immunotherapy resistance.  \nFront. Immunol. 17:1738440 .  \ndoi: 10.3389/fimmu.2026.1738440  \nCOPYRIGHT  \n© 2026 Gonz´alez-Larreategui, Valde´s-Bango Martn, Casacuberta-Serra and Soucek. This isan open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nMYC at the tumor–immune interface: mechanisms of immune escape and immunotherapy resistance  \n´Iñigo Gonz´alez-Larreategui 1, Manrique Vald´es-Bango Mart ´ın 1, S ´ılvia Casacuberta-Serra 2* and Laura Soucek 1,2,3,4*  \n1 Models of Cancer Therapies Laboratory, Vall d’ Hebron Institute of Oncology, Cellex Centre, Hospital University Vall d’ Hebron Campus, Barcelona, Spain, 2 Peptomyc S. L., Barcelona, Spain, 3 Instituci Catalana de Recerca i Estudis Avanats, Barcelona, Spain, 4 Department of Biochemistry and Molecular Biology, Universitat Autonoma de Barcelona, Bellaterra, Spain  \nImmunotherapies have transformed cancer treatment by harnessing the immune system to recognize and eliminate malignant cells, offering durable clinical beneﬁt across diverse tumor types . Despite successes with immune checkpoint inhibitors (ICIs) and other strategies like cytokines, oncolytic viruses, cancer vaccines, bispeciﬁc antibodies, and adoptive cell therapies, substantial fractions of patients still fail to respond or develop resistance. The oncogene MYC, deregulated in ~70% of human cancers, has emerged as a central driver of immune evasion and a key contributor to immunotherapy failure. MYC regulates broad transcriptional networks controlling proliferation, metabolism, angiogenesis, and cell survival, while also orchestrating profound remodeling of the tumor microenvironment (TME) . Mechanistically, oncogenic MYC suppresses antigen processing and presentation, attenuates interferon signaling, and upregulates immune checkpoints such as PD-L1 and CD47 . Concurrently, MYC stimulates secretion of immunosuppressive cytokines and chemokines that recruit regulatory T cells, myeloid-derived suppressor cells, and M2 macrophages, while driving metabolic reprogramming that fosters nutrient competition, hypoxia, and acidosis, impairing effector T-and NK-cell function. Through these pathways, MYC promotes primary, adaptive, and acquired resistance to immunotherapy. Targeting MYC, directly or indirectly, holds promise to restore immune surveillance and potentiate immunotherapeutic efﬁcacy. This review highlights MYC as a master regulator of tumor–immune interactions and underscores the therapeutic potential of MYC inhibition to overcome resistance and expand the clinical impact of cancer immunotherapy.  \nKEYWORDS  \nimmune evasion, MYC, resistance, targeted therapies, tumor microenvironment  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nImmunotherapies in cancer  \nNormally, our immune system is quite effective in controlling diseases, but it often fails to keep cancer at bay.","cbCaiva4ZDrPCUMk","https://ap.wps.com/l/cbCaiva4ZDrPCUMk","pdf",2941524,21,"English","# Immunotherapies in cancer\n## Cytokine-based therapies\n## Oncolytic viruses\n## Cancer vaccines\n## Key role of MYC at the tumor–immune interface","[{\"question\":\"Why do some patients fail to respond to cancer immunotherapy?\",\"answer\":\"Many patients fail to respond to immune checkpoint inhibitors and other immunotherapies or later develop resistance. The review links this to immune evasion mechanisms driven by the oncogene MYC.\"},{\"question\":\"How does MYC promote immune escape?\",\"answer\":\"MYC can suppress antigen processing and presentation, attenuate interferon signaling, and increase immune checkpoint molecules such as PD-L1 and CD47.\"},{\"question\":\"What strategies does the review suggest for overcoming immunotherapy resistance?\",\"answer\":\"Targeting MYC directly or indirectly is proposed to restore immune surveillance and improve immunotherapeutic efficacy, helping to overcome multiple resistance pathways.\"}]","MYC at the tumor–immune interface - mechanisms of immune escape and immunotherapy resistance | PDF",1790055057,53,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/95b6ded3d343c0eb5d6b618100f0dba2.webp",983,1389,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ac7c28b8f5597772724fcd915808dc18.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5714bf6b991d199d1b525bd781b8c12a.webp",981,1386,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3070ed10b6ba3b41afba8117f0bf4996.webp",980,1385]